Invex Therapeutics Ltd. announced the last patient has completed the 12 week dosing regimen under the Company's randomised Phase II, double- blind, placebo-controlled clinical trial examining the treatment of Idiopathic Intracranial Hypertension (IIH) with Exenatide. The Phase II clinical trial has been designed to demonstrate that Exenatide can significantly reduce intracranial pressure in IIH patients, and to gather data which will be necessary to design a subsequent registration-directed, single pivotal trial to gain regulatory clearance for the Company's reformulated Exenatide in IIH in the United States (US) and Europe. Exenatide has orphan drug designation in the US (FDA) and Europe (EMA).